Site-neutral payment has advanced from E&M to drug administration codes, but stakeholders warn rapid, simultaneous policy ...

Michael J. Daugherty writes that lawmakers should help close loopholes in the 340B program used by some Michigan hospitals.

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

The federal program was created in 1992 to help hospitals and clinics in poor communities. In recent weeks, it has become the ...

The 340B program stands at a critical crossroads in 2026. With the recent court-ordered pause of the rebate pilot program and HHS’s decision to “go back to the drawing board,” covered entities have ...

The 340B drug discount program has followed a familiar health policy trajectory. An intervention that was supposed to ease cost pressures, it instead is producing cascading unintended consequences ...

Michigan's 340B Drug Pricing Program, meant to help vulnerable patients, is being misused by hospitals, impacting care access ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

Let’s talk about 340B, the drug pricing problem that you may not have heard of, but the one that seems to have swallowed the federal budget. The program started as an attempt to help hospitals that ...

The Medicaid Drug Rebate Program and the 340B Drug Pricing Program are generally understood as separate efforts to promote drug affordability—one by directly subsidizing low-income patients through ...

On August 6, 2025, the U.S. Court of Appeals for the Second Circuit issued an opinion allowing a case challenging drug pricing changes to proceed. The case, an antitrust action brought by health ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...